Vectura Group PLC (VEC) Given Buy Rating at FinnCap
FinnCap reaffirmed their buy rating on shares of Vectura Group PLC (LON:VEC) in a research report sent to investors on Tuesday morning. FinnCap currently has a GBX 225 ($2.79) price target on the stock.
VEC has been the subject of several other reports. N+1 Singer reissued a buy rating and set a GBX 208 ($2.58) target price on shares of Vectura Group PLC in a research report on Tuesday, November 22nd. Peel Hunt reaffirmed a buy rating and issued a GBX 200 ($2.48) price objective on shares of Vectura Group PLC in a research report on Tuesday, August 30th. Numis Securities Ltd upped their price objective on shares of Vectura Group PLC from GBX 246 ($3.05) to GBX 252 ($3.13) and gave the stock a buy rating in a research report on Monday, September 19th. Finally, JPMorgan Chase & Co. reaffirmed an overweight rating and issued a GBX 230 ($2.85) price objective on shares of Vectura Group PLC in a research report on Thursday, November 24th. Eight analysts have rated the stock with a buy rating, Vectura Group PLC currently has a consensus rating of Buy and an average price target of GBX 222.13 ($2.76).
Vectura Group PLC (LON:VEC) opened at 146.60 on Tuesday. The stock’s 50 day moving average is GBX 138.77 and its 200 day moving average is GBX 147.43. The company’s market capitalization is GBX 842.51 million. Vectura Group PLC has a one year low of GBX 122.90 and a one year high of GBX 200.10.
In other Vectura Group PLC news, insider Bruno Angelici purchased 80,000 shares of the company’s stock in a transaction that occurred on Monday, September 26th. The shares were bought at an average cost of GBX 143 ($1.77) per share, for a total transaction of £114,400 ($141,917.88). Also, insider Andrew Derodra purchased 30,000 shares of the company’s stock in a transaction that occurred on Friday, September 30th. The shares were acquired at an average price of GBX 138 ($1.71) per share, for a total transaction of £41,400 ($51,358.39).
About Vectura Group PLC
Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to pharmaceutical companies.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.